Calculation of AQCmax: Comparison of five ophthalmic fluoroquinolone solutions

Current Medical Research and Opinion

Volumn 24, Issue 12, 2008, Pages 3479-3486

  Fukuda, Masamichi ^a   Sasaki, Hiroshi ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

AQCmax; Aqueous concentration; Fluoroquinolone; Gatifloxacin; Levofloxacin; Moxifloxacin; Ofloxacin; Tosufloxacin tosilate

Indexed keywords

EYE DROPS; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; TOSUFLOXACIN TOSILATE; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; BACILLUS CEREUS; CILIARY BODY; CONFERENCE PAPER; CONTROLLED STUDY; CORNEA; EYE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRIS; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; RABBIT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; THERAPY EFFECT; VITREOUS BODY; ANIMAL; ARTICLE; BACTERIAL EYE INFECTION; COMPARATIVE STUDY; DOSE RESPONSE; METABOLISM; MICROBIOLOGY; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; OPHTHALMIC SOLUTIONS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 62349092142     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802480091     Document Type: Conference Paper

References (22)

1. Sasaki K, Mitsui Y, Fukuda M, et al. Intraocular penetration mode of five fluoroquinolone ophthalmic solutions evaluated by the newly proposed parameter of AQCmax. Atarashii Ganka (J Eye) 1995;12:787-790
2. Mitsui Y, Oishi M, Sasaki K, et al. Proposal of AQCmax as a pharmacokinetic parameter for ophthalmic solutions. Atarashii Ganka (J Eye) 1995;12:783-786
3. Fung-Tomc JC, Minassian B, Kolek B, et al. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000;44:3351-3356
4. Stroman DW, Cupp G, Dahlin DC, et al. Human ocular concentrations following topical fluoroquinolones administration relative to susceptibility of ocular pathogens. Invest Ophthalmol Vis Sci 2006;47: ARVO E-Abstract 1881
5. Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 2005;123:39-44 (Pubitemid 40105427)
6. Zhanel G, Noreddin A. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 2001;1:459-463 (Pubitemid 33593833)
7. McCulley JP, Caudle D, Aronowicz JD, et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 2006;113:955-959 (Pubitemid 43795230)
8. Levine JM, Noecker RJ, Lane LC, et al. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. J Cataract Refract Surg 2004;30:2177-2182 (Pubitemid 39330678)
9. Yagci R, Oflu Y, Dincel A, et al. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye 2006;10:1038
10. Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea 2005;24:955-958 (Pubitemid 41688529)
11. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 2005;50:32-45 (Pubitemid 41657597)
12. Rookaya M, Stewart JM, Prabriputaloong T, et al. The effect of cataract surgery on ocular levels of topical moxifloxacin. Am J Ophthalmol 2004;138:554-559 (Pubitemid 39420481)
13. Fukuda M, Takahashi N. Intraocular penetration of gatifloxacin ophthalmic solution in rabbit eyes - calculation of maximum aqueous concentration (AQCmax). Atarashii Ganka (J Eye) 2004;21:1109-1112
14. Alfonso E, Crider J. Ophthalmic infections and their anti-infective challenges. Surv Ophthalmol 2005;50:1-6 (Pubitemid 41657594)
15. Langlois MH, Montagut M, Dubost JP, et al. Protonation equilibrium and lipophilicity of moxifloxacin. J Pharm Biomed Anal 2005;37:389-393 (Pubitemid 40222313)
16. Fukuda M, Sasaki K. In vitro topically applied fluoroquinolone penetration into the anterior chamber. J Jpn Ophthalmol Soc 1995;99:532-536
17. Pawar PK, Majumdar DK. Formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas. AAPS PharmSciTech 2006;7:E1-6 (Pubitemid 43338077)
18. Rathore MS, Majumdar DK. Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS PharmSciTech 2006;7:E1-6 (Pubitemid 44081020)
19. Kawazu K, Midori Y, Shiono H, et al. Characterization of the carrier-mediated transport of levofloxacin, a fluoroquinolone antimicrobial agent, in rabbit cornea. J Pharm Pharmacol 1999 Jul;51:797-801 (Pubitemid 29377951)
20. Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina 2006;26:191-195 (Pubitemid 44400716)
21. Lai WW, Chu KO, Chan KP, et al. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol 2007;144:315-318 (Pubitemid 47094713)
22. Ong-Tone L. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery. J Cataract Refract Surg 2007;33:59-62 (Pubitemid 46001538)